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ABSTRACT 
Canine osteosarcoma (OS) is a malignant neoplasia of the osteoblast, most often 
identified in the appendicular skeleton, which is both locally aggressive and highly metastatic. 
The standard of care treatment of amputation and adjuvant chemotherapy yields a median 
survival time of 10-12 months, an improvement in which has not been noted despite active 
research. The biologic behavior of cancers seems to be correlated to the state of differentiation of 
the tumor cell population. Differentiation is taken into account when a histopathologic grade is 
assigned to a particular tumor; poorly differentiated tumors acquire a higher grade and are 
expected to behave more aggressively. The tumor microenvironment contains many cells and 
signaling molecules such as cytokines, chemokines and growth factors. Investigating these 
factors may identify a stimulus for a less differentiated and more aggressive neoplasia. This is 
even more compelling if the stimulus is a druggable target.  
Fibroblast growth factors (FGFs) interact with fibroblast growth factor receptors (FGFRs) 
to initiate cell signaling that is important in embryonic development, wound healing, and 
angiogenesis. FGF2, also termed basic FGF (bFGF), plays an important role in osteoblast 
proliferation and maintaining osteoblasts in an undifferentiated state.  
We hypothesize that 1) canine OS cells will express FGFRs and FGF2, 2) FGF signaling 
blockade will attenuate pro-tumorigenic properties in OS cells, 3) FGF signaling blockade will 
cause enhanced differentiation of the OS cell lines, and 4) circulating FGF2 will be increased in 
canine OS patients compared to healthy controls and increased in dogs with osteoblastic OS 
compared to those with osteolytic OS. 
We investigated FGFR gene expression with reverse transcriptase polymerase chain 
reaction (RT-PCR) and FGF2 secretion via ELISA. The effects of FGF signaling attenuation on 
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OS cell pro-tumorigenic properties were evaluated by colorimetric proliferation assay and 
scratch migration assay. The effects of FGF signaling blockade with pan-FGFR inhibitor 
BGJ398 on OS cell differentiation were evaluated with Alizarin Red staining and quantification, 
alkaline phosphatase (ALP) bio-activity, and quantitative real time reverse transcription 
polymerase chain reaction (qRT-PCR) for osteogenic genes alkaline phosphatase (ALP), 
osterix(OSTX), osteonectin (OSN), and runt-related transcription factor 2 (RUNX2). Circulating 
FGF2 levels were quantified in the plasma of dogs with naturally occurring OS (determined to be 
osteoblastic or osteolytic based on relative bone mineral density obtained via DEXA scan) and 
healthy controls via ELISA.   
FGFR gene expression was noted in OS cell lines. FGF2 secretion was identified in all 
cell lines with secretion noted in a clear cell density-dependent manner in 2 of 3 cell lines. FGFR 
signaling attenuation inhibited OS cell migration while not affecting cell proliferation. FGFR 
signaling blockade increased differentiation in 1 of 2 cell lines evaluated, with a trend toward 
increased differentiation in the other cell line. The presence of naturally-occurring OS did not 
alter the level of circulating FGF2 in dogs. This study is the first to identify a link between FGF 
signaling attenuation and OS cell differentiation and migration in a cell line-dependent manner. 
These findings indicate that FGF blockade could be beneficial in some dogs with OS.
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CHAPTER 1 
INTRODUCTION 
 Differentiation is an important indicator of tumor grade and prognosis, with poorly 
differentiated tumors behaving more aggressively than those that are well differentiated (1–3). It 
has been postulated that forcing cancer cells into a more differentiated state represents a possible 
form of cancer treatment, as evidenced by in vitro work with a multitude of cancer types(1,4–6). 
The use of differentiation agents has been employed against some human cancers as an adjuvant 
or primary treatment, including acute promyelocytic leukemia(5) and neuroblastoma (1). In 
humans, there is a clear link between osteosarcoma (OS) grade, which includes differentiation 
status, and prognosis (7–10). This link is a challenge to prove with canine OS, as this cancer is 
commonly highly aggressive and grading systems have not accurately and reliably predicted 
prognosis (11–16).   
Fibroblast growth factors (FGFs) are a family of 18 polypeptides which interact with 
fibroblast growth factor receptors (FGFRs) to initiate cell signaling that is important in 
embryonic development, wound healing, and angiogenesis(17–25). FGF2, also termed basic FGF 
(bFGF), plays an important role in osteoblast proliferation and maintaining osteoblasts in an 
undifferentiated state (21,26,27). FGF2 has also been shown to maintain OS cells in a de-
differentiated state, contributing to their aggressiveness (28). This ligand is present in the tumor 
microenvironment, shown to be associated with tumor associated macrophages. Osteoblasts may 
also secrete FGF2(27), which could lead to autocrine and paracrine signaling if this phenomenon 
is noted in the malignant counterpart. BGJ398 is a pan-FGFR inhibitor which has been evaluated 
in several human cancer cell lines, in xenograft models, and in clinical trials (29–41). 
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The purpose of this study is to investigate the role FGF signaling plays in canine OS 
differentiation and aggressiveness. The objectives of this study were to 1) identify FGFR 
expression and FGF2 secretion in canine OS cells, 2) evaluate the effects of the pan-FGFR 
inhibitor BGJ398 on OS cell pro-tumorigenic properties, 3) determine the effects of FGFR 
inhibition on OS cell differentiation, and 4) determine if circulating FGF2 levels are higher in 
dogs with OS compared to healthy dogs, or in dogs with osteoblastic OS compared to osteolytic 
OS. 
We hypothesize that 1) canine OS cells will express FGFRs and FGF2, 2) FGF signaling 
blockade will attenuate pro-tumorigenic properties in OS cells, 3) FGF signaling blockade will 
cause enhanced differentiation of the OS cell lines, and 4) circulating FGF2 will be increased in 
canine OS patients compared to healthy controls and increased in dogs with osteoblastic OS 
compared to those with osteolytic OS. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Differentiation 
2.1.1 Overview 
 Differentiation is the process that determines the ultimate specialized phenotype and 
function of a particular cell within an organism(5). After the first several divisions of the 
fertilized egg, embryonal stem cells develop. These are considered totipotent stem cells, meaning 
that they have the ability to give rise to any tissue within the body. After many symmetric 
divisions, in which the embryonal stem cells give rise to more embryonal stem cells, the 
divisions become asymmetric – one of the daughter cells remains an embryonal stem cell while 
the other daughter cell becomes either a germinal stem cell or a somatic stem cell (progenitor 
cell). Germinal stem cells will give rise to reproductive cells such as sperm and egg, while 
somatic stem cells will ultimately give rise to the mature cells that make up the functional 
organism. The division of these more specialized stem cells remains asymmetric, with one 
daughter cell retaining the stem cell properties as the other daughter cell undergoes further 
differentiation through a series of cell divisions (transit amplifying cell). The tissue-determined 
stem cell will largely remain quiescent, as tissue renewal is primarily provided by the transit 
amplifying cells. The ultimate fate of the transit amplifying cell is to become the mature 
functional cell. As the cell divides and becomes more differentiated, the capacity for producing 
progeny of many different cell types (plasticity) is limited while specialized functions are gained. 
Terminally differentiated cells are the most highly specialized, no longer divide, and ultimately 
undergo apoptosis. 
2.1.2 Differentiation in neoplasia 
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 The determination of cancer cell differentiation is a process familiar to surgical 
pathologists, as this is an important criteria in identifying the histopathologic grade of the tumor 
(1). Well differentiated tumors structurally resemble the tissue of origin and typically carry a 
better prognosis, while poorly differentiated tumors do not resemble the tissue of origin, often 
with a concurrent reduction of cohesiveness and increased invasiveness into surrounding tissues, 
and carry a poor prognosis; tumors that are intermediately differentiated lay between. This 
spectrum of differentiation indicates that cancer cells may either de-differentiate or arise from a 
stem cell somewhere along the path of differentiation (1,3–5). The cancer stem cell theory is 
attractive, as it explains that genetic mutation is more likely to occur in a transit amplifying cell 
while it is rapidly dividing, prior to terminal differentiation, and maturation arrest at any point in 
the differentiation process will account for the degree of differentiation seen histopathologically. 
Additionally, the development of a tumor requires that the affected cells do not undergo 
apoptosis, a characteristic of stem cells that undergo asymmetric division(5). The act of tissue 
de-differentiation seems unlikely, however studies showing reversible differentiation in cell lines 
suggest this may indeed be possible(1,4,28). While the true origin of tumor differentiation status 
remains to be elucidated, the potential to target differentiation in cancer therapy remains.  
2.1.3 Differentiation therapy 
 The concept of forcing poorly differentiated cancer cells to terminally differentiate, 
leading to an inhibition of cell division and eventual apoptosis, has been investigated in many 
tumor types(5,6,42,43). Differentiation therapy is currently clinically used in the treatment of 
acute promyelocytic leukemia and neuroblastoma(42,44).  
 Retinoids, derivatives of vitamin A, have been studied for their ability to induce 
differentiation(42,44–48). Acute promyelocytic leukemia (APL) is characterized by a 
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translocation between chromosome 15 and chromosome 17 which results in a PML-RARα 
fusion protein. RARα is typically heterodimerized with its receptor RXR and a co-repressor 
complex which inhibits transcription through histone deacetylation. RARα undergoes a 
conformational change and disassociates with the co-repressor in physiologic concentrations of 
all-trans retinoic acid (ATRA) and initiates normal differentiation and maturation of myeloid 
cells. In APL, the fusion protein does not allow for sufficient disassociation from the co-
repressor and the myeloid cell differentiation is therefore arrested in the promyelocytic phase. 
Treatment with exogenous ATRA was found to induce terminal differentiation in these 
neoplastic cells and, ultimately, hematologic remission in 90% of patients (6,42,43). 
 Neuroblastoma, a childhood cancer of the sympathetic nervous system, has been found to 
spontaneously differentiate from this malignant neoplasm to a benign ganglioneuroma, a concept 
that stimulated investigation into differentiation therapy as a component of the treatment protocol 
for these children. Differentiation of neuroblastoma cells in vitrowas noted with ATRA treatment 
and a phase III clinical trial investigating maintenance high-dose pulsed 13-cis-retinoic acid, 
with better pharmacokinetics than ATRA, showed reduced relapse from minimal residual disease 
following consolidation therapy (1,44). In addition to APL and neuroblastoma, ATRA has been 
evaluated with promising results in nasopharyngeal carcinoma cells in vitro(43).  
 Additional differentiation therapies elicit their effect by altering epigenetics. Sodium 
phenylbuturate (PB) and valproic acid (VA) seem to stimulate differentiation by inhibiting 
histone deacetylation. Sodium phenylbuturate has been evaluated in patients with advanced 
cancers, showing some positive effect in patients with prostate cancer, astrocytoma, and 
myelodysplastic syndrome. Valproic acid was shown to induce differentiation in vitro in colon, 
breast, and teratocarcinoma cell lines, as well as in leukemic blasts and hematopoetic progenitor 
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cells in patients with acute myeloid leukemia. Azacytidine, a methyltransferase inhibitor, has 
been shown to induce differentiation and have a positive response in patients with 
myelodysplastic syndrome. Arsenic has been shown to initiate differentiation of APL cells, 
especially when they have become resistant to ATRA; a large portion of arsenic mechanism of 
action is thought to be through apoptosis (6,49).  
 The use of differentiation therapy in cancer, either alone, in combination with other 
differentiation agents, or as an adjuvant to traditional therapies, is an area of active research with 
interesting and sometimes clinically relevant results.  
2.1.4 Differentiation and canine osteosarcoma 
 Osteosarcoma isa mesenchymal tumor characterized by the production of osteoid and 
thought to be derived from the osteoblast. It is the most common primary bone tumor in dogs, 
accounting for approximately 85% of all skeletal malignancies(50–52). Canine OS has many 
similarities to pediatric OS, making it an attractive model for this devastating disease. These 
include the predilection for the appendicular skeleton, the presence of micrometastatic disease at 
the time of diagnosis, and similarities in treatment approach requiring surgical removal and 
chemotherapy (50,51). It is estimated that greater than 10,000 cases of canine OS are diagnosed 
in the United States each year, a higher incidence than the approximately 1,000 cases of pediatric 
OS (50,52). The frequency with which we encounter this disease in dogs allows a robust 
population for translational research. Despite decades of active research, the median survival 
time for dogs with OS has not be extended beyond the 10-12 months reported with amputation of 
the affected limb followed by adjuvant chemotherapy(52–54). While the response to treatment is 
improved in children undergoing similar treatment, the 5-year survival rate remains only 60-70% 
(50).  
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 Another similarity between pediatric and canine OS is the prevalence of histologically 
high grade tumors(50,51). There are several grading schemes for human OS which appear to 
have prognostic significance. All have a high emphasis on anaplasia within the tumor, with low 
grade tumors generally lacking this characteristic and high grade tumors carrying a loss of 
differentiation and worse prognosis (55,56). OS is often histologically heterogenous, and so if a 
portion of a low grade tumor is found to be anaplastic then it is termed “dedifferentiated” and an 
aggressive biologic course is assumed(55,56). While the literature on the significance of canine 
OS grading schemes is varied, the general trend is that a high histopathologic grade correlates 
with more aggressive biologic behavior. The grading scheme introduced by Straw et al in a 1996 
review of 51 mandibular canine OS showed no prognostic significance (57), a finding that was 
consistent when this grading scheme was used to evaluate OS of extracranial flat and irregular 
bones (14). Kirpensteijn et al developed a new grading scheme evaluating many variables 
including cellular pleomorphism, amount of matrix, tumor cell density, percent necrosis, and 
number of mitoses with consideration also given to vascular invasion, estimated whirl formation, 
and estimated multinucleated giant cells; 166 primary and 34 metastatic canine OS sampleswere 
analyzed (11). This study showed that the vast majority of these samples were high grade (grade 
III tumors made up 75% of the samples) and that grade III tumors were associated with a 
significantly shorter disease free interval and survival time. There was no significant difference 
in incidence of metastasis between grades in this evaluation. When comparing the primary tumor 
and paired metastatic lesion (n=29), no significant differences were noted among the variables 
evaluated, although the mean score for percent necrosis was significantly higher in the metastatic 
lesions when the data of all primary tumors were combined. All metastatic lesions and 26/29 
primary tumors were grade III. The clinical relevance of the previously introduced Straw grading 
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scheme was further evaluated in 140 tumor samples by Loukpolous et al., showing a significant 
correlation between high grade and several prognostic factors such as metastatic status, 
appendicular location, patient age <4 years, and non-cranial location; survival time was not 
assessed in this review(13). Degree of nuclear pleomorphism, mitotic index, and percent necrosis 
was taken into account in this grading scheme; all samples were highly pleomorphic regardless 
of grade. The Straw grading scheme was used in a study evaluating the use of doxorubicin in 
combination with BAY 12-9566, an inhibitor of matrix metalloproteinases, and no prognostic 
significance was noted (16). In a recent meta-analysis of prognostic factors in canine 
appendicular OS, histopathologic grade was not included in the variables assessed, as the effect 
of only serum alkaline phosphatase (ALP), tumor location, and age at diagnosis on outcome were 
reported most frequently (12).  
 It is thought that OS may arise from a defect in differentiation from the mesenchymal 
stem cell (MSC) to the osteocyte (10,45–47,55,58).Mesenchymal stem cells are pluripotent bone 
marrow stromal cells which can differentiate into bone, fat, cartilage, muscle, and nervous tissue. 
The MSC differentiation cascade is tightly regulated and involves many signaling pathways and 
regulatory genes. Osteogenesis is influenced early-on by signals involved in chondrogenesis such 
as bone morphogenic proteins (BMPs) -2 and -7 and FGF. Key players in osteogenic 
differentiation include osteogenic BMPs (BMPs -2, -4, -6, -7, -9), Runx-2, and Wnts. Any 
disruption along the MSC osteogenic differentiation pathway could lead to a block in 
differentiation and subsequent tumorigenesis. The potential defects are not well understood and 
may include genetic or epigenetic changes in Wnt, Rb, p53, p27, among others. If a defect leads 
to a block in differentiation, the undifferentiated OS precursor would retain the ability to 
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proliferate, creating an imbalance between proliferation and differentiation that would lead to a 
malignant phenotype (Figure 2.1)(10).  
 Differentiation therapy has been investigated in OS, with several reports of reduced 
proliferation and increased differentiation markers in human OS cell lines with various non-
specific differentiation-promoting agents(10,59). These include the nuclear receptor superfamily 
of proteins (PPARγ, retinoid, and 1,25-dihydroxyvitamin D3 activation; estrogen antagonists), 
parathyroid hormone/parathyroid related hormone (PTHrP), and BMPs with Runx-2 (BMPs 
alone did not induce differentiation). Similarly, investigations into differentiation therapy in 
canine OS has shown a reduction in tumor cell proliferation and increased differentiation 
markers with vitamin D, retinoids, BMP-2 and transforming growth factor β (TGFβ) treatment, 
although the effect varied between the cell lines(45–47,58). A study evaluating the effect of 
vitamin D3 and ATRA treatment in mouse models of primary and pulmonary metastatic OS, 
derived from the HMPOS canine OS cell line, showed a decrease in primary tumor and 
metastatic lesion weight, as well as a more osteoblastic differentiation histopathologically(48). 
As investigations into differentiation therapy progress, more specific targets may be elucidated, 
as fibroblast growth factor has in human OS(28,55,60).  
2.2 Fibroblast growth factors 
2.2.1 Structure and function 
 Fibroblast growth factors (FGFs) are a family of 18 protein ligands which mediate many 
important cellular responses. These ligands interact with fibroblast growth factor receptors 
(FGFRs) to initiate cell signaling that is important in embryonic development, wound healing, 
and angiogenesis(17–24,27,61). Fibroblast growth factors range from ubiquitous to rare 
depending on the cell type, tissue, and stage of development. Fibroblast growth factors signal 
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through the FGFRs primarily in a paracrine fashion, although autocrine and endocrine signaling 
may also occur depending on the FGF. The FGFRs are receptor tyrosine kinases (RTKs) and 
have the typical structure of an extracellular domain, a transmembrane domain, and a 
cytoplasmic domain. The extracellular ligand-binding domain is comprised of three 
immunoglobulin (Ig) like domains (D1 – D3), the “acid box” (7-8 acidic residues in the linker 
between D1 and D2), and a positively charged region in D2 which acts as a binding site for 
heparin. The interaction between FGFs and FGFRs is facilitated by heparin or heparan sulfate 
proteoglycans (HSPGs), which bind to both the receptor and the ligand, stabilizing the 
connection and acting as a reservoir for FGFs within the extracellular matrix. The D3 region of 
the extracellular domain undergoes alternative splicing in FGFRs 1-3, but not FGFR4. The N 
terminal half of D3 is static while the C-terminal half may be alternatively spliced to a IIIa or 
IIIb isoform. The IIIb isoform is expressed exclusively in epithelial tissue and the IIIc isoform is 
expressed exclusively in mesenchymal tissue. It is this specific expression of the D3 isoforms 
that allows interaction between the epithelial and mesenchymal layers in response to different 
FGFs during development. The FGFRs are promiscuous in that they may bind and become 
activated by several different FGFs, however the receptor D3 splice variant and HSPG 
interaction contribute to ligand-binding specificity.  Once the FGF/HSPG/FGFR complex is 
initiated, receptor dimerization occurs, leading to autotransphosphorylation and initiation of the 
RTK signaling cascade within the cytoplasm. This ultimately results in activation of the 
MAP/ERK pathway leading to cell proliferation, the Akt pathway leading to cell survival, and 
the PLCγ pathway leading to cytoskeletal alterations (Figure 2.2). 
2.2.2 The role of FGFsignaling in skeletal development and bone remodeling 
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 FGF signaling is important in both endochondral and intramembranous bone formation, 
as evidenced by the identification of FGFR mutations in genetic diseases that affect bone 
development (17,19,20,62). From the earliest development of the limb bud, FGF signaling has 
been identified, with the binding specificity from alternative splicing playing an important role. 
FGFR2-IIIb is expressed in the ectoderm and FGFR1-IIIc is expressed in the limb mesenchyme. 
FGF10 is expressed in the mesenchymal tissue and signals with FGFR2-IIIb to form the apical 
ectodermal ridge. FGF8 is then expressed in this ridge and signals back to FGFR1-IIIc in the 
limb mesoderm, exemplifying the reciprocal signaling required for outgrowth and patterning of 
the limb. FGFR1 and FGFR2 are expressed in mesenchymal condensation, the first morphologic 
event leading to bone formation. FGFR3 is first identified as chondrogenesis begins. Mutations 
in the FGFRs account for several human skeletal dysplasias, including dwarfing 
chondrodysplasia syndromes such as achondrodysplasia caused by FGFR3 mutation, and 
craniosynostosis syndromes characterized by premature fusion of cranial sutures. Mice that 
overexpress FGF2 develop enlarged bones, while loss-of-function inhibits bone growth. 
 FGF2 is a ubiquitous ligand and binds to all four FGFRs with highest affinity for FGFR1 
and FGFR2. It is involved in fracture repair, and activated fibroblasts in the fracture 
microenvironment express this ligand during the healing process (27,63). The effect of FGF2 on 
fracture healing appears to be dependent on the amount and duration of FGF2 exposure; limited 
exposure of FGF2 in conjunction with BMP enhanced calcification while large amounts of FGF2 
reduced the amount of bone formed and continuous FGF2 inhibited osteoblast differentiation. 
FGF2 induces osteoblast proliferation and accelerates vascularization, both aiding in fracture 
repair.  
2.2.3 FGF signaling and neoplasia 
12 
 
2.2.3.1 Overview 
 With the extensive functions of FGF signaling that allow for its significant contribution 
to embryonic development and wound healing, as well as maintenance of stem cell populations, 
it is no surprise that FGF signaling could be manipulated to enhance tumorigenesis. Specifically, 
FGF signaling has been shown to contribute to cancer cell proliferation, migration, survival and 
chemoresistance, epithelial-to-mesenchymal transition (EMT) phenotype, and 
angiogenesis(17,37,64–69). These manipulations may be acquired through the following:1) 
ligand-independent signaling by genomic alteration of FGFR (including activating mutations, 
gene translocations, or gene amplification), 2) paracrine loop formation between FGF produced 
by the tumor stroma and the FGFR due to FGFR splicing (altered ligand specificity) or 
amplification of FGFR gene (FGFR expressed out of context),3) autocrine loop development by 
increased expression of FGF ligand by the cancer cell or FGFR expression out of context so it 
has binding specificity to the autocrine FGF when it would not have otherwise, and 4) the effect 
of FGF on tumor stroma such as angiogenesis(Figure 2.3).Multiple specific incidences of FGFR 
mutations leading to tumorigenesis have been identified in human cancers, such as FGFR3 
mutations in bladder cancer and upregulation of FGFR3 in multiple myeloma (Figure 2.4). The 
effect of FGF signaling differs depending on the specific ligand-receptor binding, the tissue type, 
and the stage of development. In this vein, it is also possible to see FGF signaling as a tumor 
preventative, as is noted with FGFR2-IIIb in mouse models(64,70–72). FGF signaling has been 
evaluated in canine neoplasia to a lesser degree. Gene expression of FGFRs 1-4 and FGFR1 
protein expression was identified in canine soft tissue sarcomas (73) and a significantly higher 
concentration of FGF2 was found in the urine of dogs with bladder transitional cell carcinoma 
compared to normal dogs and dogs with urinary tract infections (74).  
13 
 
 FGF signaling inhibition may be acquired through the use of small molecule tyrosine 
kinase inhibitors (TKIs), FGFR antibodies, and FGF ligand traps(64,67,68,75). FGF ligands to 
stimulate FGFRs may be of interest in cancers where FGF2R-IIIb appears to be protective. TKIs, 
which act by inhibiting the catalytic activity of the tyrosine kinase domain by inhibiting ATP 
binding, are the most clinically relevant. There are several such inhibitors available for use, 
although the promiscuity of these TKIs often result in off-target side effects which may make 
antibodies or ligand traps more attractive.BGJ398 is a selective pan-FGFR TKI with 
predominant activity against FGFR1, FGFR2, and FGFR3,which has been evaluated in several 
human cancer cell lines, in xenograft models, and in clinical trials (29–41,76) 
2.2.3.2 FGF signaling in OS 
 FGF signaling has been evaluated extensively in human OS in recent years. FGFR 
expression has been identified in OS tumor samples,(77) and along with FGF2 in cell lines 
(78,79). A study using flow cytometry showed only low expression of FGFR1 and FGFR3 in OS 
cell lines (80). Amplification of FGFR1 was noted in 1/7 OS cell lines and 1/17 spontaneous OS 
tumor samples (76), which led to a follow-up study identifying FGFR1 amplification in 9.6% of 
primary OS tumors (81). This study showed that 18% of patients that were poor-responders to 
neoadjuvant chemotherapy had FGFR1 amplifications while none of the good-responders had 
this genetic alteration. Additionally, all of the 4 paired metastatic samples in the FGFR1 
amplification positive group also harbored this amplification. FGF1 and FGF2 stimulation has 
been shown to increase proliferation of OS cell lines (28,79,82).FGF2 was found to be highly 
expressed in OS tumor stroma and led to maintenance of OS cells in an undifferentiated state, 
increased proliferation and migration, and conferred resistance to doxorubicin chemotherapy 
(28). It has been shown that the Sox2 transcription factor inhibits Wnt signaling to maintain 
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undifferentiated osteoblasts, which appears to be regulated by FGF signaling(83). This same 
group went on to show that Sox2 is required for OS cell self-renewal and that Wnt activity is 
increased in Sox2 knock-down OS cells, a phenomenon they contribute to FGF signaling given 
the dose-dependent decrease of Sox2 noted with exposure to a FGFR inhibitor (84). OS cell 
migration was shown to be increased with cooperation between parathyroid hormone and FGF2, 
as this led to a decrease in biglycan extracellular matrix content (78). In regards to the role of 
FGF2 in OS angiogenesis, it was shown thatapurinic/apyrimidic endonuclease 1 (APE1), an 
upstream effector of angiogenesis-related molecules,upregulated FGF2-FGFR3 angiogenesis as 
shown by an increase in microvessel density (MVD) (85). Additionally, APE1, FGF2/FGFR3, 
and MVD levels correlated to a poor prognosis. Histone demethylases JMJD2B and JMJD2C 
were shown to be increased in OS cells compared to normal osteoblasts and OS tumor sample 
compared to adjacent normal (86). FGF2 was shown to be upregulated by these histone 
demethylases, in turn leading to an increase in OS cell proliferation, migration, and invasion. 
Serum FGF1 was found to be 2.5 times greater in patients with OS compared to healthy controls; 
FGF2 concentration was not significantly different, although it was found to be greater in 
patients with OS than those with osteochondroma(87,88). The FGF concentrations did not confer 
a clinical significance in these studies, however a Chinese study evaluating VEGF and FGF2 
serum levels in OS patients with and without metastasis compared to healthy controls found an 
increase in VEGF and FGF2 in OS patients compared to controls (89). The serum concentration 
of both factors decreased post-operatively, however they remained elevated compared to 
controls. The pre-operative concentrations were positively related to the size of the primary 
tumor. There was a significant difference in VEGF and FGF2 concentrations in patients with 
recurrence/metastasis compared to those without, and the pre-operative and post-operative values 
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were found to be an independent factor for recurrence or metastasis after surgery. There is 
compelling evidence that FGF signaling plays a role in human OS tumorigenesis, however this 
signaling axis has not been investigated in canine OS to date.   
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CHAPTER 3 
MATERIALS AND METHODS 
3.1 Cells and reagents 
 Three canine (Abrams, K003, HMPOS) OS cell lines were used in this study. The 
HMPOS cell line was provided by Dr. James Farese, University of Florida. The Abrams cell line 
wasprovided by Dr. Douglas Thamm, Colorado State University. The K003 cell line was 
provided by Dr. Chand Khanna, National Cancer Institute.All cell lines were cultured at 37˚C in 
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with glutamine (2 mmol/L), 
penicillin (100 IU/ml), streptomycin (100 IU/ml), and 10% fetal bovine serum (FBS) in a 
humidified atmosphere supplemented with 5% CO2. Cell cultures were maintained in 
subconfluent monolayers and passaged two to three times weekly as necessary. 
 The pan-FGFR inhibitor BGJ398 was purchased from Selleck Chemicals, Houston, TX 
(catalog# S2183). 
3.2 Canine FGFR RT-PCR 
 Total RNA was collected from Abrams, HMPOS and K003 OSA cells with a 
commercially available kit (RNeasy mini kit, Qiagen, Valencia) and 1 µg oftotal RNA was 
reverse-transcribed to cDNA (SuperScript First-Strand cDNA Synthesis Kit, Invitrogen, 
Carlsbad, CA). 5 µL ofreverse transcribed product was used as a template in a 50 µL polymerase 
chain reaction containing 10 mM of each oligonucleotide,2.5U ofTaq DNA polymerase,and 
forwardand reverse primers for canine FGFR1, FGFR2, FGFR3, and FGFR4 (Integrated DNA 
Technologies, Coralville, IA), as listed in Table 3.1.Reactions wereperformed in a PTC-200 
Peltier thermal cycler with the followingcycling conditions for FGFR1 and FGFR2: 5 minutes at 
94ºC denaturing step, followed by 40 cycles (60 seconds at 94ºC, 90 seconds at 58ºC, and 60 
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seconds at 72ºC), and concluded by 72ºC for 10 minutes. FGFR3 and FGFR4 followed similar 
cycling conditions with the exception of annealing temperatures of 61ºC and 62ºC, respectively.  
3.3 In vitro FGF2 ELISA 
 TheAbrams, K003, and HMPOS cell lines were plated in 1% FBS DMEM media at 37°C 
and 5% CO2 with seeding densities of 50,000, 25,000,12,500, and 6,500 cells per well in a 96-
well plate for 48 hours. Cell culture supernatants were collected and the concentration of 
secreted FGF2 was quantified with a commercial kit (Human FGF basic Immunoassay 
#HSFB00D, R&D Systems, Minneapolis, MN) using a monoclonal antibody specific for human 
bFGF, which was previously validated with canine urine(74). The optical density of each well 
was read 490 nm with wavelength correction set to 630 nm, yielding pg/mL of bFGF based on 
the standard curve. This was performed induplicate. 
3.4 Cell Protein Collection 
Cells were grown in culture until 80-100% confluence was attained.  Media was removed 
and cells were washed twice with PBS. Cells were exposed to trypsin for 5 minutes to detach 
from culture plate, followed by addition of complete media to neutralize the effects of trypsin. 
Alternatively, cells were manually detached with a cell scraper. Collected cells were then 
centrifuged at 2,000 rpm at 4°C for 5 minutes. Supernatant was removed and the cell pellet was 
resuspended in 1 ml PBS and transferred to a 1.8 ml eppendorf tube before centrifuging at 
10,000 rpm at for 4°C for 5 minutes. Supernatant was removed and discarded. Cell pellets were 
stored at -80°C until protein collection and quantification. Cell pellets were homogenized with 
100-150 μl commercially available Mammalian Protein Extraction Reagent (M-PER, Pierce, 
Rockford, IL) and mixed with fresh Pierce protease inhibitor cocktail solution (diluted 1:100 for 
final working solution). Homogenate was placed on a shaker at room temperature for 15 minutes 
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and then centrifuged at 10,000 rpm for 15 minutes at 4°C. Cellular protein concentrations were 
determined using a standard assay kit (Bicinchoninic Acid Protein Assay (BCA), Pierce, 
Rockford, IL). 
3.5 Cell proliferation assay 
 Abrams, HMPOS, and K003 cell lines were transferred to a 96-well plate at 
concentrations of 100,000, 50,000, 25,000, 12,500, 6, 250, 3,125 and media control per welland 
cultured overnight in DMEM supplemented with 1% FBS (1% media) to adherence.Cell 
proliferation was measured with the use of a colorimetric proliferation assay (CellTiter 96 
Aqueous One Solution Cell Proliferation Assay,Promega, Madison, WI ). Assays were 
performed in triplicate and in three separate experiments. The steepest point of the curve was 
estimated to be around 15,000 cells/well for all cell lines at 24 and 48 hours; this determined the 
seeding number for subsequent cell proliferation assays.  
 Abrams, HMPOS, and K003 cell lines were transferred to a 96-well plate ata 
concentration of 15,000 cells per well and cultured overnight in DMEM supplemented with 1% 
FBS (1% media) to adherence. Three experimental conditions for a duration of 72 hours were 
evaluated including DMEMsupplemented with 1% FBS (1% media) only, 1% media with 
BGJ398 pan-FGFR inhibitor at 200nM, and 1% media with vehicle (DMSO).  Cell proliferation 
was measured with the use of a colorimetric proliferation assay. Assay was performed in 
triplicate and in three separate experiments. The Abrams cell line was also seeded at a 
concentration of 5,000 cells per well with the same conditions in triplicate and three separate 
experiments. Based on these results, the Abrams cell line was excluded from subsequent cell 
proliferation assays.  
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 HMPOS and K003 cell lines were transferred to a 96-well plate ata concentration of 
15,000 cells per well and cultured overnight in 1% media to adherence. Eight experimental 
conditions for a duration of  24, 48, and 72 hours were evaluated including 1% media only, 1% 
media with DMSO, and 1% media with BGJ398 pan-FGFR inhibitor at 6.25 nM, 12.5 nM, 25 
nM, 50 nM, 100 nM, and 200nM.  Cell proliferation was measured with the use of a colorimetric 
proliferation assay. Assay was performed in quadruplicate and in three separate experiments. 
This was repeated at 24 and 48 hours with 12 replicates in one experiment using fluorescence to 
confirm results.  
 To determine if there was a difference in effect between two aliquots of BGJ398 pan-
FGFR inhibitor, the K003 cell line wasevaluated as noted above with each aliquot (inhibitor #1 
and inhibitor #2) in triplicate. Cell proliferation was measured with the use of a colorimetric 
proliferation assay. This experiment was performed once.  
3.6 Migration scratch assay 
Qualitative analysis of cell migration was performed using the “scratch assay” 
method(90). The Abrams, HMPOS, and K003 cell lines were grown to 80% confluence in 6-well 
plates in DMEM supplemented with 10% FBS (complete media). Three experimental conditions 
for a duration of 24 and 48 hours were evaluated including DMEM supplemented with 1% FBS 
(1% media) only, 1% media with BGJ398 pan-FGFR inhibitor at 200nM, and 1% media with 
vehicle (DMSO).A standardized acellular gap was created through cell monolayers using a 
200µL pipette tip in the middle of each well. Images of the acellular gap were captured at time 0 
(maximal gap) and 24 or 48 hours later for each experimental condition (Leica Microsystems, 
Leica Application Suite -LAS- version 2.6.R1).The average width of 5 representative acellular 
gaps per experiment conditions and cell line were used for quantitative comparisons at 24 and 48 
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hours and 3 independent experimental conditions were performed. Each of the treatment 
conditions was performed in duplicate and the assay results are representative of three separate 
experiments (HMPOS and K003) and 2 separate experiments (Abrams). Data was analyzed with 
Image J software (National Institutes of Health, Bethesda, MD). 
3.7 Differentiation Assays 
 Abrams, HMPOS and K003 cell lines were plated into 6-well plates at a concentration of 
100,000 cells per well and allowed to adhere overnight in DMEM supplemented with 10% FBS 
(complete media). The next day, the cells were washed with PBS and the culture medium was 
changed to DMEM supplemented with 1% FBS, 5% pen/strep, 100 nM dexamethasone, 10nM β-
glycerolphosphate, 550 µL ascorbic acid, termed osteogenic media (OG media).Upon 
completion of a pilot study to assess osteogenesis via Alizarin Red staining in OS cell lines at 21 
days in OG media, the Abrams cell line was no longer assessed with differentiation assays.  
 HMPOS and K003 cell lines were seeded and maintained as noted above. Three 
experimental conditions were evaluated including OG mediaonly, OG media with BGJ398 pan-
FGFR inhibitor at 200nM, and OG media with vehicle (DMSO). The medium was changed 
every third to fourth day until qRT-PCR and Alizarin Red staining/quantification at day 7, 
yielding discordant results which were concerning for cytotoxicity. To determine the 
concentration at which BGJ398 no longer influenced cell confluence, a subjective assessment of 
cytotoxicity was performed by daily microscopic evaluation of cells seeded as above and 
maintained with a titration of BGJ398 at 0 nM, 6.25 nM, 12.5 nM, 25 nM, 50 nM, and 100 nM 
for 10 days. Based on these results, experimental conditions for the subsequent differentiation 
assays were altered to include OG mediaonly, OG media with vehicle (DMSO), and OG media 
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with BGJ398 pan-FGFR inhibitor at 6.25 nM, 12.5 nM, and 25 nM. Cells were collected at days 
0, 1, 4, 7, and 10 based on the assay to be performed, as noted below. 
3.7.1 qRT-PCR 
3.7.1.1 RNA isolation 
 Total RNA was isolated from the cell monolayers using the phenol-based dissociation 
agent, TRIzol® (Invitrogen Corporation, Carlsbad, CA). 700 µL of TRIzol® was added into 
each well. The cell lysates were scraped from the cell surface, transferred to 1.5 ml eppendorf 
tubes on dry ice and stored at -80°C. 700 μL ethanol was added and the samples were mixed. 700 
µL of the mixture was loaded into a Zymo-Spin IIC Column in a collection tube and centrifuged 
at 12,000 rpm for 30 seconds. The column was moved into a second collection tube and the 
remaining 700 µL of the mixture was added and the tube was again centrifuged for 30 seconds. 
The column was moved to a new collection tube and 400 µL of RNA wash buffer was added 
followed by centrifugation for 30 seconds. A 15:1 mixture of DNA Digestion Buffer and DNase 
was vortexed and briefly centrigufed. 80 µL of this mixture was added to each sample column. 
The samples were incubated at room temperature for 15 minutes and then centrifuged. 400 µL 
Directzol RNA Prewash was added to the column which was then centrifuged, the flow-through 
was discarded, and these steps were repeated. 700 µL RNA Wash Buffer was added, the column 
was centrifuged for two minutes, the flow-through was discarded, and the column was again 
centrifuged. RNA was eluted with 50 µL DNase/RNase Free Water which was centrifuged after 
sitting for 1 minute. The flow-through was collected in a microcentrifuge tube. 
The concentration of RNA (1:40 aliquot of each sample) was determined by measuring the 
absorbance at 260 nM (A260) and 280nM (A280) in a spectrophotometer (NanoDrop 1000, 
Thermo Scientific, Waltham, MA).Total RNA was calculated as follows: 
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RNA in μg/μL = OD at 260 nM – OD at 280 nM x 40 (dilution factor) x 40 (coefficient) 
      1000 
 
3.7.1.2 Reverse transcription 
 A commercially available reverse transcription kit (Superscript III First-Strand Synthesis 
System for RT-PCR, Invitrogen) was used to generate cDNA.Briefly, the volume of each sample 
containing 1 µg of total RNA was calculated and brought up to 8 μL total with DEPC water. A 
master mix (2 μL per sample) containing 1 μL random hexamers primers and 1 μL 10 mM 
dNTPs was added into each tube. Following incubation at 65 °C for 5 minutes ( Bio-Rad DNA 
Engine Peltier Thermal Cycler ), the samples were placed on ice for 1 minute to facilitate 
binding of the oligonucleotides. A master cDNA Synthesis mix (10 μL per sample) containing 2 
μL 10x First Strand Buffer, 4 μL 25 mM MgCl2, 2 μL 0.1 M DTT, 1 μL RNase OUT and 1 μL 
(50 units) SuperScript II Reverse Transcriptase (RT) was added into each tube. The samples 
were mixed and incubated on the Thermal Cycler at 25°C for 10 minutes, 50°C for 50 minutes, 
and 85°C for 5 minutes. The samples were chilled on ice for 1 minute and then 1 μL of RNAse H 
was added to remove the RNA from the sample, leaving only cDNA. The samples were 
incubated at 37 °C for 20 minutes. The cDNA was dilute 1:5 with DEPC water to achieve 100 
µL cDNA. 
3.7.1.3 PCR amplification 
The relative expression of osteogenic genes including ALP, OSTX, OSN, RUNX2 and the 
reference gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was assessed by 
quantitative real-time reverse transcription PCR (qRT-PCR) induplicate cell layers 
(osteogenically-induced cultures) subjected to the previously noted conditionscollected on days 
0, 1, 4, 7, and 10.  
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 The primers used for qRT-PCR analysis are listed in Table 3.2 (Integrated DNA 
Technologies, Coralville, IA). Lyophilized primers were reconstituted in DEPC water to generate 
100 μM stock solution which was then diluted 1:10 to yield 10 μM working stocks.The total 
volume used for the PCR reaction was 25 μL; therefore, the final concentration of each primer 
used was 0.4 μM (or 400 nM). Quantitative real-time reverse transcription-PCR (qRT-PCR)was 
performed using 4 μL of diluted cDNA template combined a mixture composed of 12.5 μL 
Power SYBR Green PCR Master Mix(Cat# 4367659 Applied Biosystems, Foster City, CA), 1.25 
μL each of the forward and reverse primers, and 6 μL DNase/RNase-free water in a 96-well 
microplate. The reactions were performed according to the default program for SYBR green 
protocol in ABI 7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, CA).The 
level of expression for each target gene was calculated as 2 Δ Ct and the comparative ΔCt 
method was used to determine relative gene expression levels, using the day 0 OG MediaControl 
value as the nominal reference level. 
3.7.2 Alkaline Phosphatase Bio-activity 
 Alkaline phosphatase activity was assessed in duplicate samples of osteogenically-
induced cultures subjected to the previously noted conditions. At days 0, 1, 4, 7 and 10 of 
culture, the cells were harvested in 1 ml of PBS and stored as pellets at -80°C until further 
processing. The ALP activity was determined using a commercial colorimetric kit 
(SensoLytepNPP Alkaline Phosphatase Assay Kit, AnaSpec, Inc, Fremont, CA). Each sample 
was lysed with Triton X-100 and assay buffer, incubated at 4°C for 10 minutes under agititation, 
and centrifuged at 3500 rpm for 10 minutes at 4° C. The supernatants were assayed for ALP 
activity. 50 µL of a p-NitrophenylphosphatepNPPALP substrate working solution was added to 
each well of a transparent 96-well microplate. Then, 50 μL of each sample (in duplicate) and 
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standardof ALP solution was added and the plate was incubated at 37°C for 30 minutes.  
According to the manufacturer’s instructions, the absorbance was recorded at 405 nm, yielding 
ng of ALP based on the standard curve. 
 Protein concentrations were determined in aliquots of the cell extracts via BCA analysis. 
This cell layer protein was used as an index of cell number which could have varied after 
exposure to the different conditions. The relative activity of each sample was determined by 
normalizing the results of each quadruplicate sample (two experiments in duplicate) to the mean 
protein content of a duplicate BCA. Then, a mean and standard deviation were calculated for 
each quadruplicate sample. 
3.7.3 Alizarin Red staining and quantification 
 A 2% Alizarin Red solution was used in duplicate cell layers (osteogenically-induced 
cultures subjected to the previously noted conditions) to identify calcium deposition on days 7 
and 10 of exposure to OG media. Alizarin Red forms complexes with calcium ions. Following 
fixation with 10% formalin for 30 minutes, cell layers were washed 2-3 times with distilled 
water. One ml of 2% fresh Alizarin Red (Sigma-Aldrich) solution (pH 4.1) was added to each 
well. Following incubation at room temperature for 20 minutes, the stain was removed and 
washed 4-5 times with water until the rinsed solution was clear. Mineral deposits within the cell 
layers were stained bright red. Representative pictures of stained monolayers were obtained 
(Leica Microsystems, Leica Application Suite -LAS- version 2.6.R1). Plates were stored in -
20ºC. 
 Quantification was performed as previously described(91), initially with mineral oil and 
ultimately with a commercial kit (Alizarin Red S Staining Quantification Assay, 
ScienCellResearch Laboratories, Carlsbad, CA) and Parafilm M® in place of mineral oil. 
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Briefly, 800 µL 10% acetic acid was added to each well and incubated at room temperature for 
30 minutes with shaking. Cells were collected with a cell scraper, transferred to a 1.5 mL 
microcentrifuge, and vortexed for 30 seconds. Samples were sealed with Parafilm M® 
(alternatively topped with 500 µL mineral oil) and heated at 85 ºC for 10 minutes. Tubes were 
incubated on ice for 5 minutes prior to centrifugation at 14,000 rpm for 15 minutes. 500 µL of 
supernatant was transferred to a new tube and 200 µL 10 % ammonium hydroxide was added to 
neutralize the acid prior to transfer to a 96-well plate. Absorbance was read at 405 nm with a 
plate reader.  
 Protein concentrations were determined from one separate 6-well plate per cell line and 
collection day, prepared at the same time and in the same conditions, via BCA analysis. This cell 
layer protein was used as an index of cell number which could have varied after exposure to the 
different conditions. Alizarin Red S concentration was corrected for the cell protein layer by 
normalizing the results of each quadruplicate sample (two experiments in duplicate) to the mean 
protein content of a duplicate BCA. Then, a mean and standard deviation were calculated for 
each quadruplicate sample. 
3.8 PlasmabFGF ELISA 
 Heparinized plasma was collected from dogs with OS and healthy control dogs that were 
evaluated at the University of Illinois Cancer Care Clinic. All OS dogs had a diagnosis of 
appendicular OS confirmed by either histopathology or cytology with concurrent positive ALP 
staining(92). Heparinized plasma was collected at the time of initial presentation and samples 
were stored at -80°C until analysis. The OS dogs were separated into osteoblastic (n=23) and 
osteolytic (n=25) groups based on results of pre-treatment DEXA scans and the generation of 
primary bone tumor mineral density (rBMD). Primary tumors that were very osteoblastic and 
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produced a large amount of bone had rBMD> 1.4, while primary tumors that were very 
osteolytic and did not produce much bone had rBMD<0.7. PlasmabFGF was evaluated in 
treatment naïve OS dogs and ten healthy control dogs with a commercial ELISA test kit (Human 
FGF basic Immunoassay #HSFB00D, R&D Systems, Minneapolis, MN) using a monoclonal 
antibody specific for human bFGF. 
3.9 Statistical analysis 
 The distribution of the continuous variable data was evaluated using the Kolmogorov 
Smirnov test. Data that were not normally distributed were log transformed to meet the 
assumption of normality. One-way ANOVA was used to evaluate for differences between 
groups, with Dunnett’s comparison test to detect a difference between control and experimental 
conditions. When less than 12 data points were present, indicating that results of normality tests 
would not be reliable, a normal distribution was assumed.Kruskal-Wallis with Dunn’s 
comparison was used when a non-normal distribution was noted which was not corrected with 
log transformation of data.An unpaired t-test was used to compare the MTS assay results 
between each concentration of the two inhibitors. P < 0.05 was considered statistically 
significant for all analyses. Statistical analysis was carried out using a commercially available 
software program (GraphPadInStat, Version 3.10).  
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CHAPTER 4 
RESULTS 
4.1 FGFRs are expressed in osteosarcoma cell lines 
 Transcription of genes for FGFR1, FGFR2, FGFR3, and FGFR4 was identified in canine 
OS cell lines Abrams, HMPOS, and K003 (Figure 4.1). 
4.2 FGF2 is secreted by Abrams and K003 in a cell density-dependent manner 
 Active secretion of the FGF2 ligand was demonstrated by titration studies in three canine 
OS cell lines (Figure 4.2). At all cell densities evaluated, total FGF2 concentrations achieved 
physiologically relevant and active concentrations in the pg/mL range.The K003 cell line 
demonstrated the greatest capacity to secrete FGF2, approximately doubling to tripling the 
concentrations liberated by Abrams. HMPOS secreted a minimal amount of FGF2 which was not 
notably cell density-dependent.  
4.3 FGFR inhibition has no consistent effect on canine OS cell proliferation 
 To determine if abrogation of FGF signaling effects OS cell proliferation or survival, 
MTS assays were performed at varying concentrations of BGJ398. A pilot assay using BGJ398 
at 200 nM yielded a trend toward decreased proliferation with the inhibitor in HMPOS and 
K003, however inconsistent results were noted in the Abrams cell line which was therefore 
excluded from further MTS assays (data not shown). At 24, 48, and 72 hours with a titration of 
BGJ398 concentrations, no consistent difference in cell proliferation was noted in HMPOS or 
K003 cell lines at any concentration of inhibitor (Figure 4.3 a-b). HMPOS showed a significant 
increase in proliferation with BGJ398 at 50 nM, 100 nM, and 200 nM at 24 hours and with 12.5 
nM and 100 nM at 48 hours, while no significant differences were noted at 72 hours. K003 
showed variable results with a significant increase in proliferation with 12.5 nM and significant 
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decrease with 25 nM and 100 nM at 24 hours, significant increase with DMSO and decrease with 
25 nM and 50 nM at 48 hours, and no significant differences at 72 hours. 
 It was noted that the inhibitor may be expired based on the data sheet, and so a new 
inhibitor was purchased and the assay was repeated in the K003 cell line after 48 hours of 
incubation with both inhibitors. No statistically significant difference was noted (Figure 4.4) and 
a consultation with the company indicated that further quality assessment on the inhibitor 
revealed that the compound stability exceeded that which was previously published, therefore the 
first inhibitor was not truly expired. Based on these results we conclude that FGFR blockade has 
no definitive pro- or anti-proliferative effect on canine OS cells.  
4.4 Fibroblast growth factor signaling affects migration of osteosarcoma cells in vitro 
 Migration through the microenvironment to gain access to vasculature is an important 
step in cancer cell metastasis. We therefore evaluated the effects of inhibition of the FGF 
signaling pathway using BGJ398 on all three canine OS cell lines. An acellular gap was created 
in confluent cultures and the gap was measured at 24 and 48 hours after treatment. Data are 
represented as a percentage of the original gap (time 0), with 0% representing a completely 
closed gap. In the HMPOS cell line, there was a significant difference in gap closure with 
BGJ398 at the 24 hour time point (p<0.01) (Figure 4.5a). In the K003 cell line, there was a 
significant difference seen with BGJ398 at both 24 and 48 hours (p<0.01 and p<0.05, 
respectively) (Figure 4.5b). For Abrams (Figure 4.5c), the difference in gap closure with BGJ398 
approached significance at 48 hours (Dunnett’s q value=2.061, >2.33 is significant), while a 
Turkey-Kramer multiple comparison test showed a significant difference between DMSO and 
BGJ398 wells at 48 hours (p<0.01). 
4.5 FGFR inhibition increases mineralization in the HMPOS cell line 
29 
 
4.5.1 FGFR blockade causes a trend toward increased expression of osteogenic genes in 
HMPOS 
 HMPOS and K003 cell lines were exposed to OG mediaonly, OG media with BGJ398 
pan-FGFR inhibitor at 200nM, and OG media with vehicle (DMSO). qRT-PCR for osteogenic 
genes (ALP, OSN, OSTX and RUNX2) was performed at day 7, yielding inconsistent results in 
both cell lines (Figure 4.6). These findings, along with those noted in the corresponding Alizarin 
Red stain (see section 4.5.3.) were thought to be related to cytotoxicity.  Specifically, a mild 
decrease in ALP expression was noted in the HMPOS cell line with BGJ398 treatment while the 
K003 cell line showed an increase in ALP and OSN expression.A BCA assay performed on 
protein collected from plates prepared in exactly the same fashion at the same time showed a 
decrease of protein in the inhibitor well compared to the OG media control and DMSO wells 
(data not shown). To determine the concentration at which BGJ398 no longer influenced cell 
confluence, a subjective assessment of cytotoxicity was performed by daily microscopic 
evaluation of cells maintained with a titration of BGJ398 for 10 days. Percent confluence was 
recorded daily and graphed, showing that cells reached a plateau of confluence and subjective 
viability at inhibitor concentrations of 6.25 nM and 12.5 nM (Figure 4.7). 
 qRT-PCR was repeated with cells exposed to titrated concentrations of BGJ398 (6.25 
nM, 12.5 nM, and 25 nM) and collected on days 0, 1, 4, 7, and 10. FGFR blockade leads to a 
trend toward an increase in expression of osteogenic genes in the HMPOS cell line by day 10, 
while the osteogenic gene expression decreases by day 10 in the OG media and DMSO controls 
(Figures 4.8 a-d). The lack of statistical significance in the increase of osteogenic gene 
expression on day 10, despite a notable increase of the mean value, is likely due to the high 
standard deviation and the loss of the second 6.25 nM sample. The K003 cell line exhibits 
30 
 
variable and inconsistent changes in osteogenic gene expression in response to FGFR blockade, 
typically seen as a decrease in gene expression compared to control OG media (Figure 4.8 e-h), 
with the exception of a significant increase in Osterix expression in the 25 nM BGJ398 cells on 
day 10. The remaining osteogenic genes show an increase in mean value at 25 nM on day 10, 
although this change was not statistically significant.  
4.5.2 FGFR blockade increases alkaline phosphatase bio-activity in HMPOS cells 
 Alkaline phosphatase activity in the HMPOS cell linewas noted to increase in all wells on 
day 4. The increase in the inhibitor wells appeared delayed compared to the control wells. On 
day 7 there was a trend toward increased ALP activity in the 25 nM well (p=0.0722). ALP 
activity was significantly increased with all concentrations of BGJ398 compared to OG media 
control on day 10 (p<0.01) (Figure 4.9a). K003 cells showed a significant decrease in ALP 
bioactivity compared to OG media control with BGJ398 at 6.25 nM (p<0.01) and 12.5 nM and 
25 nM (p<0.05) on day 4, and with DMSO and all inhibitor concentrations on days 7 and 10 
(p<0.01) (Figure 4.9b).  
4.5.3 Alizarin Red staining intensity and concentration increases following FGFR inhibition 
 Alizarin Red forms complexes with calcium ions, therefore Alizarin Red staining was 
used to identify calcium deposition on days 7 and 10 of exposure to OG media and titrated 
concentrations of BGJ398 pan-FGFR inhibitor. A pilot study was performed to determine if 
osteogenesis would be detected in the cell lines, which were exposed to OG media alone with the 
intent to perform Alizarin Red staining at 21 days. The Abrams cell line was too aggressive and 
would not reliably survive beyond 5 days in the 6-well plates, and so this cell line was excluded 
from differentiation assays. HMPOS and K003 struggled to stay viable to 21 days, however 
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Alizarin Red staining at 18 days (K003) and 21 days (HMPOS) confirmed positive staining and 
mineral deposition (Figure 4.10).  
 HMPOS and K003 cell lines were exposed to OG mediaonly, OG media with BGJ398 
pan-FGFR inhibitor at 200nM, and OG media with vehicle (DMSO). Alizarin Red staining 
performed at day 7 showed an unexpected subjective decrease in stain intensity in the inhibitor 
wells. Corresponding quantification results were discordant to the stain intensity and the use of 
mineral oil contributed to the technical difficulty of the assay and loss of sample (Figure 4.11). 
The quantification results were discarded and the stain intensity results were concerning for 
cytotoxicity. The aforementioned BCA assay performed on protein collected from plates 
prepared in exactly the same fashion at the same timeand subjective assessment of cytotoxicity 
performed by daily microscopic evaluation of cells maintained with a titration of BGJ398 for 10 
days(see section 4.5.1) influenced the final concentrations used for the Alizarin Red assay.  
 The final Alizarin Red staining and quantification assays were then performed using a 
commercial kit with the following conditions: OG media, OG media with DMSO, and OG media 
with BGJ398 pan-FGFR inhibitor at 6.25 nM, 12.5 nM, and 25 nM. A subjective increase in 
Alizarin Red stain intensity was noted in the inhibitor wells on day 10 for the HMPOS cell line. 
Quantification confirmed a statistically significant increase in mineralization compared to OG 
media control with 25 nM BGJ398 on day 7 and with all concentrations of BGJ398 on day 10 
(Figure 4.12a-b). The difference was considered very significant with p<0.01 for all significant 
values compared to OG media control. In the K003 cell line, Alizarin Red stain intensity was not 
notably different in inhibitor wells compared to OG media control or DMSO. Quantification 
revealed an increase in Alizarin Red in the 25 nM well on day 7 which approached significance 
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(p=0.0733) and a statistically significant increase in this well compared to control on day 10 
(p<0.01) (Figure 4.12c-d).  
4.6 Osteosarcoma does not influence the concentration of circulating FGF2 
 The concentration of FGF2 was measured in heparinized plasma in treatment-naïve dogs 
with osteoblastic and osteolytic OS as well as healthy control dogs. There was no statistically 
significant difference between any of the groups (Figure 4.13) 
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CHAPTER 5 
DISCUSSION AND CONCLUSIONS 
 Fibroblast growth factor signaling plays an important role in embryonic development, 
including the maintenance of stem cells and skeletal development, as well as in wound healing 
and angiogenesis(17–24,27,60–64). Aberrant FGF signaling is involved in tumorigenesis of 
many cancer types, including OS, by contributing to cancer cell proliferation, migration, and 
invasion, maintenance of an undifferentiated state, and tumor angiogenesis(64,65,67,68,70–
72,76–79,81–86,88,89). Inhibition of FGF signaling has been shown to abrogate these properties 
in vitro with promising results in clinical trials(29–41). FGFR expression has been shown in 
canine soft tissue sarcomas(73) and the concentration of FGF2 was found to be higher in dogs 
with bladder cancer compared to normal dogs(74). Until this current investigation, FGF signaling 
has not been evaluated in canine OS.  
In keeping with what has been identified in human OS cells, canine cell lines express 
genes for all four FGFRs(77,78). While all three of the canine OS cell lines secrete FGF2, the 
response is varied. K003 and Abrams both secrete FGF2 in a cell-density dependent manner with 
K003 secreting the highest concentration. HMPOS did secrete a lower concentration of FGF2, 
although this was not cell-density dependent. The concentration of circulating FGF2 is 0.6 
pg/mL in normal conditions and up to 6 pg/mL in pathologic conditions(22). The level of FGF2 
secretion from HMPOS is negligible at about 0.4 pg/mL, less than that seen in circulation 
physiologically. The varied secretion of FGF2 between cell lines is similar to what was seen with 
human OS cells(79). While the tumor microenvironment is the most likely source of FGF2, the 
identification of FGF2 secretion by OS cells indicates that FGF signaling may occur in an 
autocrine and paracrine manner.   
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The effects of FGFR inhibition on OS cell proliferation and migration were evaluated. 
Interestingly, there was no clear time-dependent or dose-dependent effect of FGF inhibition on 
proliferation in any of the cell lines, despite the use of inhibitor concentrations that greatly 
surpassed the IC50 for all four of the FGF receptors (FGFR1=0.9 nM, FGFR2=1.4 nM, 
FGFR3=1 nM, FGFR4=60 nM(40)).  This indicates that OS cell proliferation may rely on other 
signaling pathways. FGFR inhibition showed a decrease in migration in all three cell lines which 
was significant in HMPOS and K003. This is consistent with the finding that FGF signaling 
increases migration of human OS cells(28,78). This may confer a role for FGF signaling in OS 
metastasis. Both fluorescence and colorimetric assays were used to assess proliferation; ideally, 
each replicate should have been performed with the same plate reader to allow for the most 
cohesive data. 
FGF signaling has been shown to maintain osteoblasts and human OS cells in an 
undifferentiated state(27,28,55,83,84). In this study, FGFR inhibition was used to see if a more 
differentiated phenotype may be achieved, as identified by analyzing osteogenic gene 
expression, ALP activity, and mineralization. The finding of unexpected and varied gene 
expression, a decrease in mineral production, and a decrease of protein noted in the initial 
differentiation assays at 7 days with the solitary inhibitor concentration of 200 nM was 
suggestive of cytotoxicity. This is in contrast to the results of the proliferation assay, which do 
not show a consistent cytotoxic effect of BGJ398 at 200 nM. It is possible that laboratory error 
may have contributed to the loss of cells in the inhibitor wells.Additional replicates of the 
differentiation assays with higher inhibitor concentrations may clarify this finding.  
In the final differentiation assays using the titrated doses of BGJ398 of 6.25 nM, 12.5 
nM, and 25 nM,the HMPOS cell line showed an increased expression of osteogenic genes, 
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increased ALP activity, and increased mineralization by day 10, supportive of maturation of the 
OS cells with FGFR inhibition. The difference in osteogenic gene expression was not statistically 
significant due to a large standard deviation and the loss of one of the wells at the time of cell 
collection. Ideally, this experiment should be repeated to allow for more robust statistical data. 
 The variability in response to FGFR inhibition between cell lines is again noted by the 
inconsistent response of the differentiation assays in the K003 cell line. A trend toward increased 
osteogenic gene expression was noted on day 10 at a concentration of 25 nM, with a significant 
increase in Osterix expression at this time. Osteogenic gene expression appeared decreased 
compared to control in at other concentrations and time points. ALP activity trended toward a 
decrease with FGFR inhibition. Mineralization as indicated by Alizarin Red staining and 
quantification was increased on day 10 in 25 nM BGJ398. It is possible that FGFR inhibition 
could influence K003 cell maturation and mineralization if given at higher doses and for longer 
duration.  
Reports of serum levels of FGF2 in humans with OS are varied with most failing to show 
a significant increase compared to healthy controls(87–89). Our lab has previously shown that 
serum ALP directly correlates to absolute size of the tumor burden (93)and primary tumor 
relative bone mineral density (94). This led us to investigate whether decreased tumor bone 
mineral density may correlate an increase of FGF2 in circulation, as these tumors may be less 
differentiated and therefore produce less bone. We separated dogs into osteoblastic or osteolytic 
OS based on DEXA imaging and included healthy dogs as a control. We found no significant 
difference in plasma FGF2 concentration between dogs with osteoblastic OS compared to those 
with osteolytic OS. The plasma FGF2 concentration was also not significantly different in dogs 
with OS compared to healthy controls. Evaluating the tumor stroma would be a more accurate 
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measure of FGF2, as the extracellular matrix in normal tissues and tumor associated 
macrophages in OS have been shown to harbor and secrete this ligand previously(27,28,37).  
Several limitations in our study must be addressed. Most notably, the FGFR protein 
expression was not confirmed, and evaluating cell pellets and spontaneous tissue samples with 
immunohistochemistry for these receptors, as well as FGF2, would help to solidify the presence 
of the FGF signaling axis in canine OS. Additionally, confirmation of the FGF signaling cascade 
by identifying phosphorylation of downstream targets such as Erk 1/2 would strengthen the 
findings from this study. FGF2 stimulation was not included in these assays. Both the standard 
and the osteogenic media are supplemented with fetal bovine serum (FBS), which contains FGF, 
and so stimulation may have been acquired by exposure to the media. In order to limit the effects 
of this exogenous FGF in our studies, however, media containing only 1% FBS was used in our 
assays rather than the standard 10% FBS. Performing these assays with titrated concentrations of 
FGF2 may help to confirm the results noted.  BGJ398 has not been evaluated in dogs, and so it is 
not known if the concentrations used in this study are biologically achievable and therefore 
clinically relevant. The effect of FGFR signaling inhibition on K003 differentiation was varied. 
Extending the differentiation assays to include a larger range of BGJ398 doses and extending the 
exposure to conditions to 14 days may clarify these results. While the osteogenic gene 
expression experienced a clear increase in mean values on day 10 with exposure to the inhibitor 
in the HMPOS cell line, this was not statistically significant. Increasing the number of replicates 
would allow for more robust statistical data. This study did not evaluate other key tumorigenic 
effects of FGF signaling such as cell survival/chemoresistance and angiogenesis. Evaluating the 
effect of FGF2 stimulation and FGFR inhibition on OS cells exposed to chemotherapeutics 
would enhance our knowledge of this signaling pathway in canine OS. Additionally, the effect of 
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FGF2 on OS angiogenesis may be evaluated via immunohistochemical staining of spontaneous 
tumor stroma for FGF2 expression in association with MVD. This study was primarily in vitro, 
limiting the clinical relevance. Extending this to include orthotopic murine models of canine OS 
to allow for investigation of the effect of BGJ398 treatment would further validate the use of 
FGFR inhibition for treatment of this devastating cancer in dogs.   
In conclusion, our study showed that canine OS cells express all four FGFR receptors and 
secrete FGF2, with 2 out of 3 cell lines doing so in a cell density-dependent manner. FGFR 
blockade impedes OS cell migration, however it has no clear pro- or anti-proliferative effect. 
FGF receptor antagonism led to a more mature phenotype in the HMPOS cell line, as indicated 
by an increase in osteogenic gene expression, ALP activity, and mineral production. Circulating 
FGF2 concentration is not influenced by the presence of canine OS, regardless of whether it is 
osteoblastic or osteolytic, although investigation into the tumor stroma is warranted. These 
findings indicate that FGF blockade could be beneficial in some dogs with OS.  
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FIGURES AND TABLES 
Table 3.1: Primers utilized in RT-PCR reactions 
Gene                        Sense Primer                                    Annealing Temperature 
 
Size                         Antisense Primer  
FGFR1                5’TCCAGTGGCTCAAGCACATC            58ºC 
 
(376 bp)              5’ATTTGGCTGTGGAAGTCGCTC           
 
 
FGFR2               5’GGCTCCATTAATCACACGTAC          58ºC 
 
(601 bp)             5’CCACCATACAGGCAATTAGG              
 
 
FGFR3              5’ AGGCCATCGGTATTGACAAG61ºC 
 
(383bp)             5’ GTCCCTGTGGATGCACTTCT       
 
 
FGFR4              5’TCGCATTGGAGGCATTCG                   62ºC 
 
(492 bp)            5’GTCCATGTGAGGTCCTCCTCT          
 
 
GAPDH       5’GGAAATCCCATCACCATCTTCCA          60ºC 
 
(400 bp)          5’CATCACGCCACAGTTTCCCGGAG 
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Table 3.2: Primers utilized inquantitative RT-PCR reactions 
Gene                     Sense Primer                                               
 
                       Antisense Primer                                        
RUNX2 5’ CCCGCCTTACCAAACAGTAA 
5’ CCATGTGGTTGTCAGGAGTG 
Osterix5’ GTG TGC AAC TGG CTC TTC TG   
5’ GCA GGC AGG TGA ACT TCT TC  
ALP 5’ GGACATGCAGTACGAGCTGA 
5’ TTGTCCGTGTCACTCACCAT 
Osteonectin5’ TGCCTGATGAGACAGAGGTG 
5’ AGTCCAGGTGGAGTTTGTGG 
GAPDH 5’ ATCACTGCCACCCAGAAGAC 
5’ GTGGAAGCAGGGATGATGTT 
 
 Figure 2.1 (a) The osteogenic differentiation cascade, from mesenchymal stem cells (MSCs) 
to osteocyte. Effectors in the signaling pathway are noted, including Bone morphogenic proteins 
(BMPs) and downstream mediators (inhibitor of DNA binding
tissue growth factor (CTGF)), which
important in determining osteoblast commitment and differentiation. Markers of bone formation 
include alkaline phosphatase (ALP) and Osterix (early/middle marker
osteopontin (late markers). (b) 
malignant phenotype. The potential defects are not well understood and may include genetic or 
epigenetic changes in Wnt, Rb, p53, p27, amon
differentiation, the undifferentiated OS precursor would retain the ability to proliferate, creating 
an imbalance between proliferation and differentiation that would lead to a tumorigenic 
phenotype. (Wagner ER, Luther G, Zhu G, Luo Q, Shi Q, Kim SH, et al. Defective Osteogenic 
Differentiation in the Development of Osteosarcoma. Sarcoma [Int
  
 (Id) proteins and conne
 are early markers in the cascade. Runx
s) and osteocalcin and 
Defects in the osteogeneic differentiation cascade leads to a 
g others. If a defect leads to a block in 
ernet]; 2011. Figure 1.)
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ctive 
-2 and Wnt are 
 
 
 Figure 2.2 Fibroblast growth factor (FGF) receptor tyrosine kinase signaling cascade 
resulting in (a) cell proliferation, 
M. Exploring mechanisms of FGF signal
Cell Biol. 2013 Mar;14(3):166–80. Figure 2.)
 
  
(b) cell survival, and (c) cell motility. (Goetz R, Mohammadi 
ing through the lens of structural biology. Nat Rev Mol 
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 Figure 2.3 Mechanisms of FGF signal alterations implicated in tumorigenesis. 
independent signaling by genomic alteration of FGFR. (b) FGFR splicing (altered ligand 
specificity) or amplification of FGFR gene (FGFR expressed out of context) could lead to 
paracrine loop with FGF expressed by the tumor stroma. (c) Autocrine loop may develop by the 
increased expression of FGF ligand by the cancer cell or FGFR expression out of context so it 
has binding specificity to the autocrine 
on tumor stroma such as angiogenesis. 
from development to cancer. Nat Rev Cancer. 2010 Feb;10(2):116
FGF when it would not have otherwise. (d) Effect of FGF 
(Turner N, Grose R. Fibroblast growth factor signal
–29. Figure 3.)
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(a) Ligand-
a 
ing: 
 
 Figure 2.4 Select FGFR aberrations leading to 
Wiedlocha A, Olsnes S, Wesche J. Roles of Fibroblast Growth Factor Receptors in 
Carcinogenesis. Mol Cancer Res. 2010 Nov 1;8(11):1439
  
tumorigenesis in humans. (Haugsten EM, 
–52. Figure 2.) 
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 Figure 4.1 Reverse-transcriptase polymerase chain reaction (RT
FGFR3, and FGFR4 gene transcription. Amplicons generated by RT
genes (top panels) and the house
cell lines evaluated as indicated:Lane 
Figure 4.2 FGF-2 is secreted by K003 and Abrams in a cell density
HMPOS secretes a minimal amount of FGF
 
-PCR)for FGFR1, FGFR2m 
-PCRfor FGFR1 
-keeping gene, GADPH(lower panel). Respective osteosarcoma 
1 – Abrams, Lane 2 – HMPOS, Lane3 – K003
-dependent manner. 
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– FGFR4 
 
 
-2.
 Figure 4.3 At 24, 48, and 72 hours with a titration of BGJ398 concentrations, inconsistent 
differences in cell proliferation were noted in HMPOS and K003 cell lines. 
a significant increase in proliferation with BGJ398 at 50 nM, 100 nM, and 200 nM at 
and with 12.5 nM and 100 nM at 48 hours, while no significant differences were noted at 72 
hours. (b) K003 showed a significant increase in proliferation with 12.5 nM and significant 
decrease with 25 nM and 100 nM at 24 hours, significant increase
25 nM and 50 nM at 48 hours, and no significant differences at 72 hours. *p<0.05, **p<0.01.
 
a) 
 
 
 
 
 
 
 
 
 
 
 
(a) 
 with DMSO and decrease with 
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HMPOS showed 
24 hours 
 
 
 Figure 4.3 (cont.) 
b)
Figure 4.4 There is no difference noted in K003 cell proliferation at any concentration when 
comparing inhibitor #1 and inhibitor #2. 
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 Figure 4.5 Treatment with BGJ398 inhibits cell migration in a scratch
cells were scratched and then treated with 200 nM BGJ398. Coverage of
documented by photomicrographs after incubation for 24 and 48 hours. 
BGJ398 inhibited scratch closure in the 
Treatment with BGJ398 significantly inhibited the 
hours (*p < 0.05).(c) In the Abrams
which was not significant.  
 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 assay. A monolayer of 
 the defect 
(a) 
HMPOS cell line after 48 hours (**
K003 cell line at 24 hours (**
 cell line, a trend toward inhibited scratch closure was noted 
47 
by cells was 
Treatment with 
p < 0.01).(b) 
p < 0.01) and 48 
 
 Figure 4.5 (cont.) 
b) 
c
48 
 
 Figure 4.6 qRT-PCR for osteogenic genes (
after exposure to OG media, OG media + 
(a) A mild decrease in ALP expression was noted in the HMPOS cell line with BGJ398 
treatment. (b) The K003 cell line showed an increase in ALP and 
treatment. 
a)
b)
ALP, OSN, OSTX, and RUNX-2) was performed 
200 nM BGJ398, and OG media + DMSO for 7 days
OSN expression with 
49 
. 
BGJ398 
 
 Figure 4.7 The effect of a titrated concentration of BGJ398 on microscopic evaluation of cell 
confluency as a subjective measure of cytotxicity showed a plateau of cell confluence at 6.25 and 
12.5 nM for both HMPOS and, more notabl
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
y, K003 cell lines.  
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 Figure 4.8 qRT-PCR for osteogenic genes (ALP, OSN, OSTX, and RUNX
after exposure to titrated concentrations of BGJ398 (6.25 nM, 12.5 nM, and 25 nM) for 0, 1, 4, 7, 
and 10 days. (a-d) HMPOS cells treat
expression of osteogenic genes by day 10, while the expression decreases by day 10 in the OG 
media and DMSO controls. (e
expression following BGJ398 treatment
compared to control OG media, with the exception of a 
25 nM BGJ398 cells on day 10 
show an increase in mean value at 25 nM on day 10
p<0.05, ** p<0.01. 
 
a) 
  
-2) was performed 
ed with BGJ398 exhibit a trend toward an increase in 
-h)K003 cells exhibit variable changes in osteogeni
, typically seen as a decrease in gene expression 
trend toward increased expression 
which is significant in OSTX. The remaining osteogenic genes 
 which was not statistically significant.
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c gene 
in the 
 * 
 
 Figure 4.8 (cont.) 
b)
c)
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 Figure 4.8 (cont.) 
d)
 
 
e)
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 Figure 4.8 (cont.) 
f)
 
 
 
 
g)
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 Figure 4.8 (cont.) 
h)
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 Figure 4.9 The effect of BGJ398 on alkaline phosphatase activity was evaluated at days 0, 1, 
4, 7, and 10. (a) HMPOS ALP bioactivity increased significantly at all concentrations of the 
inhibitor on day 10. (b) K003 ALP bioactivity decreased 
on day 4 and with DMSO and all concentrations of the inhibitor on days 7 and 10. ALP 
concentration normalized to protein content and expressed both as a ratio and as fold difference 
to better visualize changes. 
a)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
with the inhibitor at all concentrations 
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 Figure 4.9 (cont.) 
b) 
Figure 4.10 Pilot study with positive Alizarin Red staining confirms that K003 and HMPOS 
show signs of mineralization with osteogenic media over time. 
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 Figure 4.11 Effect of 200 nM
and K003 showed a subjectively decreased stain intensity with a discordant increase in 
quantification.  
a) 
b) 
 BGJ398 on differentiation of canine OS cells. 
58 
(a-b) HMPOS 
 
 
 Figure 4.12 The effect of BGJ398 on mineralization on OS cell lines was assessed 
subjectively with Alizarin Red stain intensity and conf
experienced a statistically significant increase in mineralization with
and with (b) all concentrations of BGJ398 on day 10. 
increased mineralization with 25 nM BGJ398 on day 7 and a 
mineralization with 25 nM BGJ398 on day 10
concentration normalized to protein content and express
to better visualize changes. 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
irmed with quantification
(a)25 nM BGJ398 on day 7 
(c-d) K003 experienced a 
(d)significant increase in 
.Microscopic images at 10x magnification. 
ed both as a ratio and as fold difference 
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. (a-b) HMPOS 
(c)trend toward 
ARS 
 
 Figure 4.12 (cont.) 
b) 
c) 
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 Figure 4.12 (cont.) 
d) 
 
Figure 4.13 Circulating FGF-2 concentration is not influenced by presence of osteoblastic or 
osteolytic osteosarcoma.  
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